Senior Product Manager, Liom

Salary not provided

+ Equity

JIRA
Senior and Expert level
San Francisco Bay Area
Liom

Real-time biomarker and drug monitoring

Open for applications

Liom

Real-time biomarker and drug monitoring

21-100 employees

HealthcareB2BAnalyticsBiologyMachine LearningMedTech

Open for applications

Salary not provided

+ Equity

JIRA
Senior and Expert level
San Francisco Bay Area

21-100 employees

HealthcareB2BAnalyticsBiologyMachine LearningMedTech

Company mission

To reach the holy grail of continuous, non-invasive, and medical-grade multi-biomarker monitoring, in a next-generation wearable, providing us with data to live longer, healthier lives.

Company mission

To reach the holy grail of continuous, non-invasive, and medical-grade multi-biomarker monitoring, in a next-generation wearable, providing us with data to live longer, healthier lives.

Few candidates hear
back within 2 weeks

Our take

For many in the healthcare space, it has been determined that personalised medical care is the next step in improving patient outcomes around the globe. Liom (previously Spiden) is looking to be a part of this next generation of healthcare, providing wearables that continuously monitor biomarkers and drugs in the blood.

Smartly, the company has chosen to target glucose first. This gives them an entry to the glucose monitoring device market that represents a growing proportion of the $50 billion diabetes care sector. Beyond this, Liom's combination of advanced spectral techniques and data analysis, alongside its "novel approach for technology miniaturisation", sets it up to expand into any number of healthcare branches and niches.

Early in 2024, Liom announced a breakthrough in its research, with its team achieving test results that showed only a 9% Mean Absolute Relative Difference (MARD) from the gold-standard measurement. It has also secured $15 million in additional funding which will support the conclusion of its first R&D phase.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Funding (last 2 of 4 rounds)

Dec 2024

$25m

SERIES A

Jan 2024

$15m

CONVERTIBLE

Total funding: $65.3m

Leadership

Leo Grünstein

(Founder & CEO)

Co-founder and Board Member at Caeli Nova, and Chairman at LG Capital. Former Co-founder and Board Member at MoneyPark, and also worked at McKinsey & Company as an Engagement Manager.

Diversity, Equity & Inclusion at Liom

  • Diversity & equal opportunity: With 18 nationalities in the company, we strive to build a highly diverse and exciting environment. We take special care of gender diversity - currently balanced at 50/50 among the permanent employees.

Job (1)

All locations

Product